Ignite Creation Date:
2024-05-05 @ 10:23 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005843
Status:
COMPLETED
Last Update Posted:
2013-02-11
First Post:
2000-06-02
Brief Title:
R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Phase II Trial of R115777 NSC-702818 an Inhibitor of Farnesyl Protein Transferase in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Status:
COMPLETED
Status Verified Date:
2007-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase II trial to study the effectiveness of R115777 in treating patients who have metastatic pancreatic cancer Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
Detailed Description:
OBJECTIVES
I Determine the safety and effectiveness of R115777 in patients with metastatic pancreatic cancer
II Determine the response rate time to progression and 6 month survival rate of these patients with this treatment regimen
III Assess the pharmacokinetics of this treatment regimen in this patient population
OUTLINE This is a multicenter study
Patients receive oral R115777 twice daily for 21 consecutive days Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 1 year
I Determine the safety and effectiveness of R115777 in patients with metastatic pancreatic cancer
II Determine the response rate time to progression and 6 month survival rate of these patients with this treatment regimen
III Assess the pharmacokinetics of this treatment regimen in this patient population
OUTLINE This is a multicenter study
Patients receive oral R115777 twice daily for 21 consecutive days Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 1 year
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| FCCC-00005 | None | None | None |
| NCI-45 | None | None | None |
| CDR0000067859 | REGISTRY | PDQ Physician Data Query | None |